NCT00578955View on ClinicalTrials.gov

Comparative Study of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone to Treat Subjects With Blepharoconjunctivitis

PHASE3CompletedINTERVENTIONAL
Enrollment

417

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Blepharoconjunctivitis
Interventions
DRUG

1% Azithromycin and 0.1% Dexamethasone

Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.

DRUG

1% Azithromycin

Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.

DRUG

0.1% Dexamethasone

Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.

All Listed Sponsors
lead

Sun Pharmaceutical Industries Limited

INDUSTRY

NCT00578955 - Comparative Study of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone to Treat Subjects With Blepharoconjunctivitis | Biotech Hunter | Biotech Hunter